Piper Jaffray Companies restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Monday, TipRanks reports.
Several other equities research analysts have also recently weighed in on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a hold rating to a buy rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a buy rating in a research note on Friday, August 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $44.25.
NASDAQ:TBPH traded down $0.01 during trading hours on Monday, hitting $23.77. 278,300 shares of the company traded hands, compared to its average volume of 247,635. Theravance Biopharma has a twelve month low of $15.18 and a twelve month high of $35.48. The firm has a 50-day moving average of $20.88 and a 200 day moving average of $20.65. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -5.96 and a beta of 1.72.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale boosted its stake in Theravance Biopharma by 64.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 7,500 shares in the last quarter. Fosun International Ltd increased its holdings in Theravance Biopharma by 78.0% in the 2nd quarter. Fosun International Ltd now owns 185,899 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 81,434 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Theravance Biopharma by 882.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 8,951 shares in the last quarter. CWM Advisors LLC acquired a new position in shares of Theravance Biopharma in the 2nd quarter valued at $167,000. Finally, SG Americas Securities LLC bought a new position in shares of Theravance Biopharma during the 1st quarter worth about $156,000. Institutional investors and hedge funds own 84.16% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Article: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.